We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


The Enduring Success of Hybridoma-based Antibody Development

The Enduring Success of Hybridoma-based Antibody Development content piece image

Since its original development in 1975, hybridoma technology encourages researchers all over the world to share their antibodies with one another, unlocking a vast amount of potential for biological research.

Due to their high selectivity, monoclonal antibodies (mAbs) are used in a wide range of disciplines, including research, diagnostics and therapeutic applications. Despite the advancement of modern antibody generation technologies, hybridoma-based antibody production continues to be a leading approach for mAb discovery and development.

Download these whitepapers to explore:

  • The key benefits of using hybridoma-based antibody development
  • Perceived misconceptions relating to hybridoma technology
  • Alternative approaches that currently exist for mAb generation